Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Satralizumab in pediatric AQP4 antibody-positive NMOSD (phase III, open-label PK and efficacy study)
2019-004092-39Phase 3Active
- Sponsor
- Roche
- Start
- Dec 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of satralizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by Roche. Primary endpoint: Observed serum satralizumab trough concentrations. Started Dec 2021; status: active.
02
Drugs
satralizumab
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on 2019-004092-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004092-39.